Compass Therapeutics Analyst Ratings
Compass Therapeutics: A Buy Rating on Promising Pipeline and Solid Financials
Compass Therapeutics Analyst Ratings
Buy Rating Affirmed for Compass Therapeutics on Strong Financials and Promising Clinical Trials
Compass Therapeutics Analyst Ratings
Analysts Offer Insights on Healthcare Companies: SAB Biotherapeutics (SABS) and Compass Therapeutics (CMPX)
Buy Rating on Compass Therapeutics for Breakthrough in Resistant Tumor Treatment
Compass Therapeutics' Strategic Advancements and Strong Financials Prompt Buy Rating
Compass Therapeutics Analyst Ratings
Analysts' Top Healthcare Picks: Compass Therapeutics (CMPX), Guardant Health (GH)
Optimistic Outlook: Buy Rating on Compass Therapeutics Amid Positive Clinical Development Milestones
Analysts Offer Insights on Healthcare Companies: PepGen Inc. (PEPG), 4D Molecular Therapeutics (FDMT) and Compass Therapeutics (CMPX)
Analysts Conflicted on These Healthcare Names: HUTCHMED (HCM), Bayer (OtherBAYRY) and Compass Therapeutics (CMPX)
HC Wainwright & Co. Reiterates Buy on Compass Therapeutics, Maintains $10 Price Target
Compass Therapeutics Analyst Ratings
Analysts Have Conflicting Sentiments on These Healthcare Companies: Compass Therapeutics (CMPX), Pacira Pharmaceuticals (PCRX) and Bluejay Diagnostics (BJDX)
SVB Securities Keeps Their Buy Rating on Compass Therapeutics (CMPX)
H.C. Wainwright Reaffirms Their Buy Rating on Compass Therapeutics (CMPX)
SVB Securities Remains a Buy on Compass Therapeutics (CMPX)
HC Wainwright & Co. Reiterates Buy on Compass Therapeutics, Maintains $10 Price Target
No Data